Blueblood Ventures Limited has scheduled its 19th Annual General Meeting for Wednesday, September 30, 2026. The meeting will be held at the company’s registered office in New Delhi to transact ordinary business items.

The primary agenda includes the adoption of the standalone audited financial statements for the financial year ended March 31, 2026. Shareholders will also consider the re-appointment of Managing Director Suresh Bohra, who retires by rotation at this meeting.

Meeting Details

The AGM is scheduled to commence at 11:30 am at M-55, M Block Market, 3rd Floor, Greater Kailash-2, New Delhi. The register of members and share transfer books will remain closed from September 23, 2026 to September 30, 2026.

Corporate members intending to send authorized representatives are requested to provide a certified true copy of the board resolution authorizing their attendance and voting rights.

Director Re-appointment

Suresh Bohra seeks re-appointment as a director pursuant to Section 152 of the Companies Act, 2013. He has been with the company since his first appointment on February 23, 2007.

Mr. Bohra holds a commerce graduate degree and a post-graduation in management. He brings over 25 years of experience in loan syndication, project financing, and equity placement. His leadership has guided the company’s diversification from securities trading to real estate.

Blueblood Ventures Limited reported a 4.5x increase in net profit for FY26, driven by higher revenue and improved other income. The company’s shares remain suspended on the BSE following regulatory non-compliance issues dating back to 2022.

The SME-listed entity posted a total revenue of ₹110.64 lakh for the financial year ended March 31, 2026, up from ₹80.08 lakh in FY25. Net profit after tax rose significantly to ₹3.26 lakh, compared to ₹0.59 lakh in the previous year. This improvement was supported by a reduction in employee benefits expense and finance costs, despite a sharp increase in other expenses.

Financial Performance

Revenue from operations grew by nearly 58% to ₹79.18 lakh, while other income remained stable at ₹31.46 lakh. The company recorded a profit before tax of ₹4.27 lakh, against ₹0.81 lakh in FY25. Total expenditure stood at ₹106.36 lakh, up from ₹79.27 lakh.

What the Numbers Show

Other income constituted 28.4% of total revenue in FY26, indicating a continued reliance on non-operating streams such as interest income (₹21.46 lakh) and miscellaneous income (₹9.99 lakh). While revenue from operations expanded, "other expenses" surged to ₹97.03 lakh from ₹10.72 lakh in FY25, largely driven by ₹93 lakh in business promotion costs. This expense growth nearly offset the gains from operational revenue expansion, highlighting a shift in cost structure rather than pure operational efficiency.

Balance Sheet and Regulatory Status

As of March 31, 2026, the company held long-term borrowings of ₹9,400 lakh, primarily comprising zero-coupon optionally convertible debentures. Short-term borrowings decreased to ₹50.91 lakh from ₹292.93 lakh. Trade receivables fell to ₹1,398.69 lakh from ₹2,127.41 lakh, while long-term loans and advances increased to ₹6,346.28 lakh.

Trading in Blueblood Ventures’ securities has been suspended since November 21, 2022, due to non-compliance with SEBI regulations. The company received a show-cause notice in December 2025 regarding potential compulsory delisting and has submitted a waiver application to the BSE, which remains pending. No dividend was declared for FY26.